Anybody buy the $5800 report that has Sirona profiled below in the abstract? Lol. We are the only company mentioned in the abstract below.
Folks, it is looking like we are now on the global radar of the big market players. With the right news, we could blow. Operative words "right and could".
The prospects right now are very interesting. If this keeps up, and for the right price, I would support a buyout. Its really the only exit strategy for the large holders, and we all know who they are. The scientific value is far outstripping managements current resources capability to penetrate market pipelines at a required pace vis a vis demand, and that is where the play is.
"Dyschromia refers to a condition marked by any irregular discoloration on the skin, hair or nails, which can present as single or multiple light or dark patches on the skin. A large part of the dyschromia treatment market is saturated and highly generalized. There is an unmet need for more efficacious and safer treatment options, as the available treatments are associated with poor efficacy, low patient compliance, and problematic safety profiles. For instance, Sirona Biochem Corp.’s TFC-1067 demonstrates superior efficacy to hydroquinone, the gold standard, for the treatment of dyschromia. At present, hydroquinone is the gold standard treatment for skin lightening, despite known toxicity, which is an ongoing concern for the FDA and the dermatology community."